Online inquiry

IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5481MR)

This product GTTS-WQ5481MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets tcdB gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_003434531.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299394
UniProt ID P18177
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5481MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2662MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ358MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ6395MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CT-011
GTTS-WQ10205MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ4360MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ9464MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ9710MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64407564
GTTS-WQ5288MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD124
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW